Eagle Pharmaceuticals have been granted their U.S. Patent No. 11,103,483 titled, “Formulations of Bendamustine”, by the U.S. Patent and Trademark Office (USPTO). Eagle plans to submit this patent to be included in the FDA’s (Food and Drug Administration’s) Orange Book for both BENDEKA® and BELRAPZO®. Eagle believes that various Orange Book-listed patents against Slayback Pharma LLC, Apotex Inc. et al, Mylan Laboratories Limited, and Fresenius Kabi USA, LLC, are associated with Eagle’s new drug submissions that mention BENDEKA. The United States Court of Appeals has since affirmed that the contending patents are legitimate and valid, strengthening Eagle’s intellectual property rights for their issued patents.
Read more here.
Don’t miss the next article from HealthFirst 100.
Join our mailing list to receive the latest posts from our blog directly in your inbox.